Is tamoxifen the Rosetta Stone for breast cancer?

Journal of the National Cancer Institute

Volumn 95, Issue 5, 2003, Pages 338-340

  Jordan, V Craig ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ANTIESTROGEN; AROMATASE INHIBITOR; ESTROGEN RECEPTOR; FULVESTRANT; ONCOPROTEIN; PROTEIN TYROSINE KINASE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TRANSFORMING GROWTH FACTOR BETA; UBIQUITIN;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER STAGING; CANCER SURVIVAL; CELL COMMUNICATION; CELL SURFACE; CLINICAL TRIAL; DRUG CHOICE; DRUG EFFICACY; DRUG RECEPTOR BINDING; EDITORIAL; GENE EXPRESSION; GENE TARGETING; HORMONE ACTION; HUMAN; NONHUMAN; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROTEIN SYNTHESIS;

EID: 0037420201     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/95.5.338     Document Type: Editorial

References (26)

1. Harper MJ, Walpole AL. A new derivative of triphenylethylene: effect on implantation and mode of action in rats. J Reprod Fertil 1967;13:101-19.
2. Jordan VC. Designer estrogens. Sci Am 1998;279:60-7.
3. Jordan VC. Tamoxifen: a most unlikely pioneering medicine. Nat Rev Drug Discov. In press 2003.
4. Osborne CK. Tamoxifen in the treatment of breast cancer. N Engl J Med 1998;339:1609-18.
5. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 1998;351:1451-67.
6. Osborne CK, Bardou V, Hopp TA, Chamness GC, Hilsenbeck SG, Fuqua SA, et al. Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst 2003;95:353-61.
7. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002;359:2131-9.
8. Shang Y, Brown M. Molecular determinants for the tissue specificity of SERMs. Science 2002;295:2465-8.
9. Font de Mora J, Brown M. AIB1 is a conduit for kinase-mediated growth factor signaling to the estrogen receptor. Mol Cell Biol 2000;20:5041-7.
10. Newman SP, Bates NP, Vernimmen D, Parker MG, Hurst HC. Cofactor competition between the ligand-bound oestrogen receptor and an intron 1 enhancer leads to oestrogen repression of ERBB2 expression in breast cancer. Oncogene 2000;19:490-7.
11. Wijayaratne AL, McDonnell DP. The human estrogen receptor-alpha is a ubiquitinated protein whose stability is affected differentially by agonists, antagonists, and selective estrogen receptor modulators. J Biol Chem 2001;276:35684-92.
12. Pearce ST, Liu H, Jordan VC. Modulation of ER function and stability by tamoxifen and a critical amino acid D538 in helix 12. J Biol Chem. In press 2003.
13. List HJ, Lauritsen KJ, Reiter R, Powers C, Wellstein A, Riegel AT. Ribozyme targeting demonstrates that the nuclear receptor coactivator AIB1 is a rate-limiting factor for estrogen-dependent growth of human MCF-7 breast cancer cells. J Biol Chem 2001;276:23763-8.
14. Lauritsen KJ, List HJ, Reiter R, Wellstein A, Riegel AT. A role for TGF-beta in estrogen and retinoid mediated regulation of the nuclear receptor coactivator AIB1 in MCF-7 breast cancer cells. Oncogene 2002;21:7147-55.
15. Reiter R, Wellstein A, Reigel AT. An isoform of the coactivator AIB1 that increases hormone and growth factor sensitivity is overexpressed in breast cancer. J Biol Chem 2001;276:39736-41.
16. Knabbe C, Lippman ME, Wakefield LM, Flanders KC, Kasid A, Derynck R, et al. Evidence that transforming growth factor-beta is a hormonally regulated negative growth factor in human breast cancer cells. Cell 1987;48:417-28.
17. Butta A, MacLennan K, Flanders KC, Sacks NP, Smith I, McKinna A, et al. Induction of transforming growth factor beta 1 in human breast cancer in vivo following tamoxifen treatment. Cancer Res 1992;52:4261-4.
18. Osborne CK, Coronado-Heinsohn EB, Hilsenbeck SG, McCue BL, Wakeling AE, McClelland RA, et al. Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. J Natl Cancer Inst 1995;87:746-50.
19. Lee ES, MacGregor Schafer J, Yao K, England G, O'Regan RM, de los Reyes A, et al. Cross resistance of triphenylethylene-type antiestrogen but not ICI 182,780 in tamoxifen-stimulated breast tumors grown in athymic mice. Clin Cancer Res 2000;6:4893-9.
20. Howell A, Robertson JF, Quaresma Albano J, Aschermannova A, Mauriac L, Kleeberg UR, et al. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 2002;20:3396-403.
21. Osborne CK, Pippen J, Jones SE, Parker LM, Ellis M, Come S, et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol 2002;20:3386-95.
22. Yao K, Lee ES, Bentrem DJ, England G, Schafer JI, O'Regan RM, et al. Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice. Clin Cancer Res 2000;6:2028-36.
23. Jordan VC. What if tamoxifen (ICI 46,474) had been found to produce rat liver tumors in 1973? A personal perspective. Ann Oncol 1995;6:29-34.
24. Jordan VC. Tamoxifen and tumorigenicity: a predictable concern. J Natl Cancer Inst 1995;87:623-6.
25. Jordan V, Morrow MM. Re: Trends in use of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States 1975-1999. J Natl Cancer Inst. In press 2003.
26. Peto R, Boreham J, Clarke M, Davies C, Beral V. UK and USA breast cancer deaths down 25% in year 2000 at ages 20-69 years. Lancet 2000;355:1822.